Rationale: Despite improved understanding of the underlying genetics, pulmonary arterial hypertension (PAH) remains a severe disease. Extensive remodeling of small pulmonary arteries, including proliferation of pulmonary artery smooth muscle cells (PASMCs), characterizes PAH. MicroRNAs (miRNAs) are noncoding RNAs that have been shown to play a role in vascular remodeling.
P ulmonary arterial hypertension (PAH) is a disease of the small pulmonary arteries (PAs), characterized by an increase in PA pressure and vascular remodeling leading to a progressive increase in pulmonary vascular resistance. 1 The consequence of vascular obliteration is right heart failure and high mortality. 2, 3 Germline mutations in the gene coding for the bone morphogenetic protein (BMP) type-2 receptor (BMPR2), a receptor for the transforming growth factor (TGF)-␤ superfamily, have been identified in approximately 70% of patients with the heritable form of PAH (hPAH). 4 Moreover, BMPR2 expression is markedly reduced in PAH cases in the absence of mutations in this gene (idiopathic PAH, iPAH). In pulmonary artery smooth muscle cells (PASMCs), mutations in BMPR2 are associated with an abnormal growth response to BMPs and TGF-␤. 5 In pulmonary artery endothelial cells (PAECs), these mutations increase the susceptibility of cells to apoptosis. 4, 6 The absence of BMPR2 mutations in some families and in the majority of iPAH cases suggests that further pathological mechanisms still need to be identified. One of the main histopathologic features common to all forms of PAH is the accumulation of cells expressing smooth muscle specific ␣-actin (SMA) in peripheral pulmonary arteries. This includes the appearance of SMA-positive cells in the neointima and the extension of SMA-positive cells into precapillary pulmonary arterioles that are normally devoid of smooth muscle. 7
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MicroRNAs (miRNAs) are a class of small, endogenous and noncoding RNAs able to negatively regulate gene expression by targeting specific messenger RNAs (mRNAs) and induce their degradation or translational repression. 8, 9 A recent study has defined mRNA degradation as the predominant mechanistic effect of miRNA:mRNA targets. 10 Several recent studies have assessed the direct role of miRNAs in vascular inflammation and in the development of vascular pathologies. 11, 12 In a recent study, miR-145 was shown to be abundantly expressed in the vessel wall. 13 miR-145 is transcribed as a long pri-miRNA encoding both miR-143 and miR-145 on human chromosome 5 14 and on mouse chromosome 18, regulated by a conserved SRF-binding site. 15 Localization of miR-145 to the vessel wall demonstrated high expression in the smooth muscle layer in comparison with adventitial fibroblasts and endothelial cells. 13 For this reason, miR-145 is considered a smooth muscle cell phenotypic marker and modulator, able to regulate SMC through its target gene KLF-5 and its downstream signaling molecule, myocardin. 13, 16 Agonists within the TGF-␤ superfamily have been shown to activate miR-143/145 cluster via a Smaddependent pathway. 17, 18 The analysis of miR-145, miR-143, and miR-143/145 knock-out (KO, Ϫ/Ϫ) mice showed a noticeably thinner smooth muscle layer of arteries. 16 This leads to moderate systemic hypotension. 15, 16 Moreover, vascular smooth muscle cells (VSMCs) isolated from single and double knockout animals showed hyperproliferative activity and a higher ability to migrate toward platelet-derived growth factor, a known chemoattractant for VSMCs. 15 A pharmacological analysis of the vasculature of miR-143/145Ϫ/Ϫ mice revealed a blunted response to vasopressive stimuli. 15, 16 miRNAs are therefore critical regulators of cardiovascular cell differentiation, growth, proliferation, and apoptosis. miR-NAs are likely candidates as critical regulators of vascular remodeling in PAH, a topic that we have recently reviewed. 19 In our previous publication 20 we did not see any dysregulation of miR-145 in rat lung when assessed by quantitative PCR (q-PCR), but we did not assess this miRNA in mouse or human models, nor did we further investigate miR-145 in further detail in rat models. In the present study, in consideration of the importance of miR-145 in smooth muscle cell biology, we examined the expression and function of miR-145 in the development of PAH. We show that miR-145 is significantly upregulated in mice in response to chronic hypoxia and that genetic ablation or anti-miR-driven pharmacological reduction of miR-145 is protective against the development of PAH in mice. A whole transcriptome microarray study on isolated pulmonary arteries was used to quantify the transcriptional response to hypoxia. In human tissues, we show elevation of premature and mature forms of miR-145 in tissues and isolated PASMCs obtained from PAH patients with a mutation in the BMPR2 gene compared with controls. On the basis of these observations, we propose a critical role for miR-145 in the development of PAH.
Methods
An expanded Methods section is available in the Online Data Supplement.
Animal Models and In Vivo Modulation of miRNAs
miR-145Ϫ/Ϫ mice have previously been described. 15 Homozygous miR-145Ϫ/Ϫ female mice or age-matched wild-type controls (strain C57BL6J/129SVEV, 8 weeks of age) were exposed to chronic hypoxia for 14 days or maintained in normoxic conditions and assessed at 10 weeks of age.
BMPR2 R899X Knock-In Mice
Knock-in mice harboring a heterozygous truncating mutation in BMPR2 were used to further determine the regulation of miR-145. These mice, similar to previously described R899X transgenic mice, 21 develop spontaneous pulmonary hypertension.
The LNA anti-miRs were 16 nucleotides in length targeting base 2 to 17 of mature miR-145/143 and were as fully phosphorothiolated oligonucleotides perfectly complementary to the 5Ј region of either miR-143 or miR-145 and were synthesized as a mixer of LNA and DNA. The LNA control oligonucleotide (scramble) consisted of a sequence directed against a Caenorhabditis elegans-specific miRNA with a comparable LNA/DNA content. Anti-miR and control oligonucleotides were administered to female C57Bl6 mice (8 -10 weeks old) via subcutaneous injection (25 mg/kg in 0.2 mL saline). Mice were injected with oligonucleotide or vehicle on days 1 and 8 of the 14-day hypoxic exposure.
Statistical Analysis
For all the q-PCR experiments, values are expressed as fold change or meanϮSD. All data were analyzed using a 2-way ANOVA followed by Bonferroni post hoc test, 1-way ANOVA followed by Bonferroni post hoc test, or unpaired t test as appropriate, as described in figure legends (*PϽ0.05, **PϽ0.005, ***PϽ0.001).
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Results
Expression of miR-145 in a Mouse Model of PAH
We first performed in situ hybridization to localize miRNA within the lung of control mice because this has not previously been evaluated. We observed positive staining for miR-145 within the smooth muscle layer of vessels and bronchi in the lungs of wild-type (WT) mice ( Figure 1A ). We next assessed the expression of miR-145 in the total lung and the right ventricle obtained from WT mice exposed to hypoxia for 14 days and compared this with normoxic controls to evaluate whether miR-145 was altered during response to injury in these tissues. Our analysis revealed a significant upregulation of miR-145 in response to hypoxia both in lung and the right ventricle ( Figure 1B and 1C, respectively). miR-143 levels were also upregulated in the same tissues (Online Figure IA and B ). Analysis of miR-145 expression in the brain, kidney, and spleen of the same animals did not reveal any dysregulation (Online Figure IIA , B, and C). Thus, miR-145 is expressed in smooth muscle cells in the lung of mice and is upregulated in response to hypoxia selectively in the lung.
Quantification of the Development of PAH in miR-145؊/؊ Mice Compared With Controls
We next evaluated the effect of genetic ablation of miR-145 on the development of PAH. Eight-week-old miR-145Ϫ/Ϫ mice and control age-matched mice were exposed to chronic hypoxia or maintained in normoxic conditions for 14 days and evaluated for the development of PAH using a series of in vivo measurements. The absence of miR-145 expression in the lungs of the KO animals used in the study was confirmed by q-PCR and in situ hybridization (Online Figure IIIA and B). Because miR-145 is transcribed in its pri-form clustered with miR-143, we also analyzed WT and KO animals for the expression of miR-143 under both normoxic and hypoxic conditions to ensure that miR-143 levels were not substantially altered in the lung after genetic ablation of miR-145 and in response to hypoxic insult. q-PCR analysis of miR-143 expression in RNA extracted from the total lung of WT and miR-145Ϫ/Ϫ mice showed no difference in response to hypoxia between WT and miR-145Ϫ/Ϫ animals (Online Figure IV) . Thus, any changes in the development of PAH in response to hypoxia in miR-145Ϫ/Ϫ are specific to the selective loss of miR-145. We next quantified the development of PAH in WT and miR-145Ϫ/Ϫ mice in response to chronic hypoxia. In WT mice, we observed a significant and expected increase in systolic right ventricular pressure (RVP) and right ventricular hypertrophy (RVH) (Figure 2A and 2B). In contrast, miR-145Ϫ/Ϫ animals displayed no increase in systolic RVP or RVH (Figure 2A and 2B). Interestingly, there was no difference in baseline systolic RVP or RVH between WT and miR-145Ϫ/Ϫ mice (Figure 2A and 2B). Measurements are also presented in Online Tables I and II . Histological analysis showed the presence of pulmonary vascular remodeling in small PAs of WT animals after exposure to hypoxia but this was reduced in lungs harvested from miR-145Ϫ/Ϫ animals, a finding confirmed by quantitative scoring ( Figure 2C and 2D). Therefore, genetic ablation of miR-145 protects mice against the development of PAH in response to hypoxia. The mean systemic arterial pressure (SAP) was lower in miR-145Ϫ/Ϫ mice compared with controls, as expected and consistent with previously published work. 15, 16 Neither the WT nor miR-145Ϫ/Ϫ mouse SAP were altered by exposure to hypoxia (Online Figure VA) , and no changes were observed in the heart rate of the WT or miR-145Ϫ/Ϫ mice exposed to hypoxia (Online Figure VB) .
Figure 1. miR-145 localization in mouse lung section and expression in normoxic versus hypoxic mice. A, In situ hybrid-
ization showing miR-145 localization in mouse lung. Paraffin sections were rehydrated and incubated with an anti-miR-145 or scramble probe as negative control. For colocalization, ␣-actin was detected in the same samples using an immunohistochemistry assay, with nonimmune isotype-IgG antibody as negative control. Images ϫ100 or ϫ400 magnification, scale barsϭ50 m. B and C, q-PCR analysis of normoxic and 14 days hypoxic WT mice. Total RNA was extracted from the total lung (B) or the right ventricle (C) of normoxic (white bars) or hypoxic (black bars) 10-week-old mice; 6 mice per group were analyzed. Every sample was tested in triplicate. Results were normalized to U6 values and expressed as relative fold change, with an arbitrary value of 1 assigned to the control group. Data were analyzed using an unpaired t test (***PϽ0.001 versus control samples).
Analysis of miR-145 Predicted Targets in the Lungs of miR-145؊/؊ Mice Compared With Controls
To verify the effect of miR-145 ablation on gene and protein expression, several miR-145 gene targets, already validated in the literature or identified using TargetScan and PicTar prediction algorithms and selected for their potential involvement in PAH, were analyzed by q-PCR in lung tissue of WT and miR-145 KO animals. They included KLF4 and KLF5 (Kruppel-like factor 4 and 5), both involved in SMC proliferation and differentiation, and SMAD4 and SMAD5, signaling intermediaries for the TGF-␤ superfamily. Analysis of RNA revealed a significant upregulation of both SMAD4 and SMAD5 in miR-145Ϫ/Ϫ normoxic mice in comparison with wt normoxic mice (Online Figure VIA and B). KLF4 was elevated both in normoxic and hypoxic miR-145Ϫ/Ϫ mice, whereas KLF5 expression was significantly upregulated in WT hypoxic versus miR-145Ϫ/Ϫ hypoxic mice (Online Figure VIC and D). The Western blot analysis of KLF4 protein expression in WT and KO animals in hypoxic conditions confirmed the significant upregulation of this target, whereas no significant changes were observed in normoxia (Online Figure VII) . In contrast, the KLF5 protein level was not significantly upregulated in the same samples both in normoxic and hypoxic conditions (Online Figure VII ).
Microarray Analysis of Gene Expression Profile in the PAs of miR-145؊/؊ Mice in Comparison With WT Animals
Global transcriptome analysis was performed with 6 samples from each of the miR-145Ϫ/Ϫ hypoxic, WT hypoxic miR-145Ϫ/Ϫ normoxic and WT normoxic groups. Potential miR-145 targets with 3ЈUTR miRNA binding regions as predicted in at least 3 of the databases in miRWalk and significant false discovery rates in the miR-145Ϫ/Ϫ hypoxic versus WT hypoxic comparison were selected for further analysis. Ingenuity pathway analysis software and the Database for Annotation, Visualization, and Integrated Discovery (DAVID) were used to select targets that are present in pathways relevant to pulmonary hypertension. A total of 13 targets were selected for validation by real-time PCR, using these selection criteria (Online Table III ). The validated miR-145 targets FSCN1, DAB2, and ACE were selected for further analysis. 13, [22] [23] [24] Real-time PCR validated 13 of the targets selected from the microarray (Online Figure VIII) . The WT hypoxic group showed significantly increased expression versus all other groups for 7 of the targets TGFB2, FRZB, ACE, CTGF, ANGPTL4, AP2B1, and ITGBL1 (Online Figure VIII) . Further, the q-PCR data reflected the changes between groups observed in the microarray for WIF1, CAMK2A, TTN, ACE, DAB2, and FSCN1 (Online Table  III ) and showed that these changes were significant (Online Figure VIII) . The changes observed in the microarray were not validated for TMOD1 and APH1A (not shown). The validated targets were categorized into 5 groups: inhibitors of Wnt signaling (WIF1, FRZB, DAB2), regulation of actin cytoskeleton (FSCN, TTN), transcriptional regulation (CAMK2A), cell adhesion (ITGBL1, CTGF), and endothelial function (ACE, ANGPTL4). Further analysis from the array data revealed marked changes in many components of the WNT signaling pathway (Online Table IV ). We used primary human PASMC cultures to manipulate miR-145 using anti-miR and pre-miR strategies. Concordant regulation of targets was observed by miR145 manipulation in vitro (Online Figures IX and X) . Since previous studies have demonstrated that p53 can regulate miR-143 and miR-145, 25 we assessed p53 levels in WT and KO animals. Although p53 mRNA levels were enhanced in response to hypoxia in both WT and KO animals, no differences between WT and KO animals were observed (Online Figure XI) .
Quantification of the Development of PAH in WT Mice Treated With an miR-145 Anti-miR in Comparison With Controls and WT Mice Treated With an miR-143 Anti-miR
To determine if the protective effect against the development of PAH observed in miR-145 ablated mice in response to chronic hypoxia can be replicated by pharmacological manipulation of miR-145, 8-week-old female C57Bl6 mice were injected subcutaneously with an anti-miR specific for miR-145 or miR-143 and then exposed for 2 weeks to chronic hypoxia and compared with vehicle-and scramble-treated mice. A second dose was injected at day 8 of hypoxic exposure. The selective and substantial downregulation of miR-145 or miR-143 in the treated animals was confirmed in the lung by q-PCR ( Figure 3A and 3B ). Scramble-treated mice showed no change in the expression of both miR-143 and miR-145 ( Figure 3A and 3B) . Northern blot confirmed selective downregulation ( Figure 3C through 3F) . We next evaluated the development of PAH in treated mice in comparison with controls. In vehicle-treated hypoxic mice, we observed a significant and expected elevation in systolic RVP and RVH in comparison with vehicle-treated normoxic mice (Figure 4 ). The same effect was observed in scramble-treated and anti-miR-143 animals; however, mice treated with anti-miR to miR-145 showed a significant reduction in systolic RVP ( Figure 4A) . No changes were observed in RVH and SAP in anti-miR-145-treated or anti-miR-143-treated mice ( Figure 4B ), despite substantially reduced levels of the miR-145 in the right ventricle and left ventricle plus septum observed by q-PCR (Online Figure XII) . Histological analysis showed a significant reduction of pulmonary vascular remodeling in small PAs of anti-miR-145-treated mice exposed to chronic hypoxia in comparison with the percentage of remodeling observed in vehicle-or scramble-treated mice exposed to hypoxia ( Figure 4C and 4D) . These data show that selective pharmacological manipulation of miR-145 but not miR-143 prevents the development of PAH in mice exposed to hypoxia. No changes in mean SAP were observed (Online Figure XIIIA) . No changes across the groups were observed in the heart rate (Online Figure XIIIB) .
miR-145 in Human PAH
We next assessed whether miR-145 is expressed in lung tissue taken from patients with PAH and examined the expression levels in the lungs of patients with iPAH and hPAH and compared this with control lung tissue. We first extracted miRNA from paraffin-embedded lung tissue. Compared with controls, miR-145 was significantly elevated in both hPAH and iPAH samples ( Figure 5A ). We next used in situ hybridization to localize expression of miR-145 in human lungs selected from the above patient groups (Figure 5B). In concordance with analysis of the mouse lungs, expression of miR-145 in control lung sections was confined to smooth muscle cells, including both vascular and bronchiolar lineages ( Figure 5B ). PAH is characterized by the development of both concentric and plexiform arterial lesions involving the pre-acinar and intra-acinar pulmonary arteries. In patients with iPAH and hPAH, miR-145 was expressed by arterial smooth muscle cells and observed within the muscular component of concentric lesions and plexiform vascular lesions wherever present ( Figure 5B ). miR-145-positive cells were also observed in pre-acinar and intra-acinar arteries where vessels had become muscularized ( Figure 5B ). In addition, newly muscularized arterioles at the level of alveolar ducts expressed abundant miR-145 ( Figure 5B ). Although in situ localization is not quantitative, we also observed that miR-145 expression was notably reduced in neointimal myofibroblasts compared with more differentiated SMCs resident within the medial layer (for example, see Online Figure XIV ). Taken together, in human lung, miR-145 is expressed predominantly in the smooth muscle cell compartment and this was confirmed by colocalization studies (Online Figure XV) , although we cannot rule out expression in other cells such as vascular endothelium. miR-145 expression is also observed within remodeled vessels of complex lesions in patients with hPAH and iPAH. In some vessels, levels of miR-145 appear reduced in neointimal cells.
Because the growth and characteristics of PASMCs isolated from patients with BMPR2 mutations is fundamentally different from those isolated from patients without germline mutations, we used human primary cells in culture to assess the effect of BMPR2 mutations on miR-145 regulation. We therefore cultured primary human PASMCs obtained from PAH patients and quantified miRNA levels at the pre-miRNA and mature miRNA levels. Both the preform of miR-145 as well as the mature form were significantly elevated in cells derived from patients with known BMPR2 mutations compared with unaffected controls (Figure 6A and 6B) . We next performed Northern blot analysis to confirm and quantify the differential levels of the mature miR-145 in the same samples. In concordance with the PCR analysis, miR-145 was significantly elevated in RNA extracted from patients with mutations in BMPR2 compared with nonmutated control PASMCs ( Figure 6C and 6D) . Therefore, basal levels of miR-145 are elevated in patients with germline BMPR2 mutations.
Effect of BMPR2 Downregulation on miR-143 and miR-145 Expression in Human PASMCs and Regulation of miR-145 in Cell Culture
Davis-Dusembery et al recently reported that BMP4 is able to induce the expression of the miR-143/145 cluster through the CArG box present in its promoter. 17 We decided to evaluate C57Bl6 mice treated with an anti-miR specific for miR-145 or miR-143, scrambled anti-miR, or vehicle and exposed to chronic hypoxia for 14 days. C, Pulmonary arterial remodeling measured in the same groups (nϭ4); nϭnumber of mice. Data were analyzed using a 1-way ANOVA followed by Bonferroni post hoc test (*PϽ0.05, **PϽ0.005, ***PϽ0.001). D, Representative pulmonary arteries stained with elastic-Van Gieson. Images all ϫ40 magnification, scale barsϭ20 m.
in vitro the effect of a siRNA-mediated knock-down of BMPR2 on miR-143 and miR-145 expression level in human WT PASMCs. Cells were therefore transfected with a short interfering (si) sequence, able to target and downregulate specifically BMPR2, or with an siScramble as negative control. RNA was extracted from these samples and from untreated cells after 72 hours for comparison. The downregulation of BMPR2 induced the significant upregulation of both miR-143 and miR-145, whereas no changes were observed in untreated or siScramble-treated cells (Online Figure XVI) , suggesting that miR-145 acts downstream of BMP signaling in PASMC. Pathway analysis from our transcriptional profiling from in vivo samples resulted in some transcriptional changes in the BMP signaling pathway at the RNA level (Online Figures XVII and XVIII) .
We also assessed the reverse to the above and asked whether miR-145 modulation in PASMC in vitro had an effect on BMPR2 expression. Anti-miR-driven downregulation or miR145 mimic-delivery miR-145 failed to influence expression of BMPR2 gene expression (Online Figure XIXA  through D) . Furthermore, although ID1 expression was upregulated in response to BMP4, modulation of miR-145 by an anti-miR had no influence on ID1 gene expression (Online Figure XIXE) . We also confirmed this is primary PASMC from a patient with IPAD (Online Figure XX) . To correlate this with in vivo evidence, we also assessed BMPR2 levels, SMAD1/5/8 phosphorylation, and ID1 expression from in vivo tissues from the knockout study discussed above; 145 knockout had no effect (Online Figure XXI) .
Taken together, this suggests that miR-145 acts downstream of BMPR2 signaling.
We assessed the effect of hypoxia on miR-145 levels in both PASMC and PAECs but did not observe any effects at 3 different time points in either cell type (Online Figure  XXII) . Neither upregulation nor downregulation of miR-145 in PASMC influenced cell migration under our experimental conditions (Online Figure XXIII) , although we observed a reduction in PASMC proliferation in the presence of miR-145 mimic delivery (Online Figure XXIV) .
miR-145 Expression in BMPR2 R899X Mice
Considering the importance of miR-145 regulation in the mouse models of PAH and in PASMCs extracted from PAH patients with a mutation in the BMPR2 gene, we evaluated the effect of a truncating BMPR2 mutation on miR-145 expression in heterozygous R899XϮ mice. RNA was extracted from the whole lung of 6-month-old mice and analyzed by q-PCR and Northern blot for miR-145. This revealed a significant upregulation of miR-145 in the mutated mice compared with controls ( Figure 7A through 7C) . In situ localization of miR-145 in paraffin lung sections confirmed positive staining within the smooth muscle layer of pulmonary vessels and bronchi of both WT and BMPR2-mutated mice, with strong staining observed in mutated animals ( Figure 7D ).
Discussion
We describe the expression and regulation of miR-145 in the lung under normal conditions and in response to hypoxic injury. In the hypoxic mouse model, we show elevation of miR-145 levels in total lung and in the right ventricle compared with controls. Moreover, we demonstrate that genetic ablation of miR-145 prevents the development of PAH. This occurred in the absence of any modulation of miR-143, thus confirming the importance of miR-145 in the development of PAH. To confirm this protective effect of miR-145, we measured PAH development also in wt mice treated with an anti-miR specific for miR-145 and exposed to chronic hypoxia, observing again a significant reduction in the systolic RVP of the treated hypoxic animals in comparison with untreated mice exposed to the same environment. A substantial downregulation of miR-143 with a specific anti-miR did not show a similar effect suggesting a particular importance for miR-145 in PAH. In human samples from patients with hPAH and iPAH, we show elevated miR-145 levels. Localization studies revealed miR-145 expression in SMCs of complex lesions. We further demonstrate a specific association between BMPR2 mutations and elevated levels of miR-145 in PASMCs extracted from PAH patients and in the lungs of mice mutated in this gene. Thus, we suggest an essential role for miR-145 in the development of PAH.
Recently, several studies pointed out not only the specific smooth muscle localization of this miRNA but also its fundamental role in the differentiation of this cell type. In particular, miR-145 has been identified as the most abundant miRNA in normal arteries and in differentiated VSMCs. 13 Considering the central role of PASMCs in remodeling in the small peripheral, normally nonmuscular PAs during the development of PAH, we decided to evaluate the effect of the ablation of this miRNA in mice exposed to hypoxia. In particular, we used knockout mice deleted for the sequence coding for miR-145 but able to express miR-143, transcribed in the same precursor. This is relevant because a recent study shows how the introduction of miR-145 but not miR-143 into neural crest stem cells was sufficient to guide 75% of cells into the VSMC lineage within only 24 hours. 26 This suggested a predominant role of miR-145 in SMCs differentiation, leading us to use a single miR-145Ϫ/Ϫ in this study to evaluate its role in the development of PAH. Cell culture studies in both PASMC and PAEC failed to show an effect of hypoxia per se on expression levels of miR-145. This suggests that miR-145 is expressed in both compartments, but the regulation cannot simply be induced in isolated cell compartments in vitro. This is consistent with recent data 27 demonstrating the important interactions in vivo between vascular cells through miR-145-mediated cellular communication. Our cell culture studies in isolated primary PASMC failed to show an effect of miR-145 modulation on cell migration, although we did observe an inhibition of cell proliferation by miR-145 mimic delivery. Further studies are required to detail such phenotypes in detail, but it is likely that complex cell:cell interplay in vivo is relevant to the regulation of cellular changes that lead to vascular remodeling in the development of PAH, as has been observed in other vascular pathological settings. 27 A functional analysis of the vasculature of miR-145Ϫ/Ϫ mice revealed a reduced pulmonary vascular response to chronic hypoxia and reduced right ventricular hypertrophy. In addition, the percentage of remodeled vessels was significantly reduced in the knockout animals, strongly suggesting a protective role for miR-145 ablation in PAH development. The similar protective effect was observed in WT mice treated with an anti-miR able to reduce miR-145 expression substantially. Interestingly, we did not observe an effect of miR-145 anti-miR on RVH in the setting of anti-miR delivery to wild-type mice. This may be due to inefficient target derepression using our dosing regimen or the possibility that residual miR145 is able to negate this effect compared with knockout animals. This will require further analysis to assess these possibilities. Moreover, we demonstrated significant upregulation of this miRNA in both hPAH and iPAH and in particular in BMPR2-mutated PASMCs extracted from hPAH patients. A similar level of miR-145 upregulation was also identified in mice carrying a mutation in this gene. This conserved dysregulation suggests the presence of a link between the regulation of miR-145 and the TGF-␤ superfamily, already known to be involved in the maturation process of other miRNAs, including miR-21, through the interaction of SMAD proteins with DROSHA during the second step of miRNA biogenesis. 28 Very recently, this link has been proved with the observation that both TGF-␤ and BMP4 are able to activate transcription of the miR-143/145 cluster through the CArG box present in its promoter, though via a different mechanism. In fact, MRTF-A was shown to be essential for BMP4-dependent induction of the cluster, whereas TGF-␤ enhances miR-143/ 145 expression via SRF and MYOCD expression. 17, 18 Interestingly, despite the upregulation of miR-145 in the lung tissues of the analyzed PAH patients, the in situ localization of this miRNA in the vessels of iPAH and hPAH patients showed abundant miR-145 expression in hypertrophied arteries, pulmonary vascular lesions, and newly muscularized arterioles. The lack of neointimal expression of miR-145 is consistent with the presence of a dedifferentiated mesenchymal cell in the neointima. However, lack of miR-145 profoundly impedes the development of a neointima in the mouse carotid injury model 15 due to diminished migratory activity of SMCs. The mouse hypoxic model is a model of distal muscularization of the pulmonary circulation rather than neointima formation. Nevertheless, taken together, our findings and results in the systemic circulation suggest that inhibition of miR-145 may perturb both the process of muscularization and neointima formation. It is also interesting that upregulation of miR-145 in the PASMCs obtained from iPAH patients has been recently noted in another study, 29 confirming our findings. However, in that study, the focus was on the role of miR-204 in PAH, without further analysis of miR-145 expression and regulation.
We did not observe an effect on the prevention of PAH in WT mice treated with an anti-miR to miR-143, suggesting a predominant role for miR-145 in the development of PAH. There are previous studies showing that miR-145 and miR-143 KO do not always have the same effect on phenotype. In vitro, antago-miR-mediated inhibition of miR-145 expression blocked the ability of myocardin to convert fibroblasts into VSMCs, with a less substantial effect by miR-143 knock-down. 26 Moreover, the upregulation of miR-145 (but not miR-143) in neural crest stem cells was sufficient to induce the conversion of Ϸ75% of cells into VSMCs. 26 In vivo, abnormalities in the vessel wall of the aorta and other arteries, noticeably thinner than those of WT animals, were observed in miR-145 and miR-143/145 double KO mice but not in miR-143 mice. 15 Further studies are warranted to confirm the predominance of miR-145 over miR-143 in this setting.
Our studies suggest that miR-145 is acting downstream of BMP signaling because modulation of miR-145 in vitro and in vivo failed to influence BMPR2 levels or components of the BMP signaling axis. In contrast, downregulation of BMPR2 using siRNA in PASMC elevated miR-145 levels. Dysregulation of several miRNAs in pathological samples (animal or human) in PAH is now clear, with each miRNA having many hundreds of potential gene targets. This defines a complex transcriptional situation with multiple pathways and cell types potentially involved. Several studies recently showed the important role of KLF4 and KLF5 in SMC proliferation and differentiation. In particular, Cheng et al studied the capacity of miR-145 to control neointima lesion formation through the regulation of KLF5. 13 Cordes et al showed that miR-143 and miR-145 can repress several factors (including KLF4 and 5) that normally promote the less differentiated, more proliferative smooth muscle phenotype. 26 In the present study, we show that KLF4 and 5 expression correlate with miR-145 regulation, with a significant upregulation of both these targets in hypoxic miR-145 knockout mice. However, it is not possible to evaluate this process in the hypoxic mouse because of the lack of neointima formation in this model. In our study, we evaluated global gene expression in response to genetic depletion of miR-145 to clarify the mechanism behind the protective effect of this depletion against the development of PAH. The resistance of miR-145Ϫ/Ϫ mice to hypoxia induced PAH seems likely to be due to differential regulation of multiple direct and indirect miR-145 targets. However, the validation of direct miR-145 targets 13, [22] [23] [24] 30 and direct or indirect miR-145 targets points to the modulation of specific pathways. Most notably, 3 validated targets from the WT hypoxic versus miR145Ϫ/Ϫ hypoxic comparison inhibit canonical Wnt/␤-catenin signaling. WIF1 and FRZB bind to Wnt proteins in the extracellular space and prevent ligand-receptor interactions, 31, 32 whereas DAB2 stabilizes phosphorylated axin and attenuates Wnt/␤-catenin signaling by increasing proteasomal degradation of ␤-catenin. 33 These factors inhibit Wnt signaling leading to decreased expression of Wnt target genes, such as cyclin D1 (CCND1) and E cadherin (CDH), which were also found downregulated in the miR145Ϫ/Ϫ hypoxic group (Online Table II ). Downregulation of CDH and CCND1 can cause cytoskeletal reorganization and decreased proliferation, respectively. 34, 35 It was previously reported that Wnt signaling can drive a program of smooth muscle differentiation in the lung, including the pulmonary vasculature. 36 In agreement with analysis of in vivo tissues, we also observed regulation of targets at the mRNA level in PASMC with miR-145 manipulation via both anti-miR and pre-miR overexpression strategies. Therefore, inhibition of Wnt/␤-catenin signaling may contribute to the phenotype observed in hypoxia in the miR145Ϫ/Ϫ mice and is worthy of further detailed investigations.
Despite the complexity, the manipulation of individual miRNAs, however, such as miR-145 in the present study, or miR-204, 29 appears to exert a substantial impact on the development of PAH. For this reason, our study also highlights the potential for miR-145 downregulation as a novel therapeutic approach for PAH. Strategies to achieve this may require selective delivery to the pulmonary system to avoid potentially deleterious effects of downregulation of miR-145 in the peripheral vasculature. Our in situ studies in mouse and human show expression of miR-145 in the smooth muscle cells of the lung and within vascular lesions associated with PAH. Hence, strategies to deliver selectively within the lung are attractive. Because miR-145 is also expressed in bronchial smooth muscle cells, the effect on bronchial tone remains to be evaluated. Taken together, the results of this study have demonstrated an essential role for miR-145 in the development of PAH through remodeling associated with the SMC compartment and association of elevated miR-145 levels in patients and mice with mutations in the BMPR2 receptor.
